A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6

Abstract Objectives: To assess the efficacy and tolerability of bicalutamide 150mg (‘Casodex'1‘Casodex' is a trade mark of the AstraZeneca group of companies. 1 ) as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with early (T1b–T4, any N, M0) prostate cancer. Methods: This randomised, double-blind study was conducted in the Nordic countries as part of the ‘Casodex' Early Prostate Cancer programme. Patients received bicalutamide 150mg ( n =607) or placebo ( n =611) in addition to standard care. Results: More than 80% of patients had not received therapy of primary curative intent. Median follow-up in both groups was 3 years. Median exposure to study treatment in the bicalutamide and standard care alone groups was 2.5 and 2.3 years, respectively. Bicalutamide reduced the risk of objective disease progression by 57% compared with standard care alone (HR 0.43; 95% CI 0.34, 0.55; p ⪡0.0001). Survival data were immature (11.4% deaths) with no difference between the two treatment groups. Conclusions: Bicalutamide 150mg as immediate therapy, either alone or as adjuvant to treatment of curative intent, significantly reduces the risk of disease progression in patients with early prostate cancer. The trial is ongoing to assess whether the reduction in risk of objective progression translates into an overall survival benefit.